Top Purchase Related
Home
>
Node
>
Subnode

Chemical process evolution of efavirenz, a potent non-nucleosidal HIV reverse transcriptase inhibitor

Chen, C.Y.; Tan, L.

Enantiomer 4(6): 599-608

1999

ISSN/ISBN: 1024-2430
PMID: 10672461
Document Number: 506655

Document emailed within 1 workday
Secure & encrypted payments

Lalezari, J.P.; DeJesus, E.; Northfelt, D.W.; Richmond, G.; Wolfe, P.; Haubrich, R.; Henry, D.; Powderly, W.; Becker, S.; Thompson, M.; Valentine, F.; Wright, D.; Carlson, M.; Riddler, S.; Haas, F.F.; DeMasi, R.; Sista, P.R.; Salgo, M.; Delehanty, J. 2003: A controlled Phase Ii trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults Antiviral Therapy 8(4): 279-287
Antinori, A.; Zaccarelli, M.; Cingolani, A.; Forbici, F.; Rizzo, M.G.; Trotta, M.P.; Di Giambenedetto, S.; Narciso, P.; Ammassari, A.; Girardi, E.; De Luca, A.; Perno, C.F. 2002: Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure Aids Research and Human Retroviruses 18(12): 835-838
Engchanil, C.; Kosalaraksa, P.; Lulitanond, V.; Lumbiganon, P.; Chantratita, W. 2006: Multi-drug resistant HIV-1 reverse transcriptase genotype in children treated with dual nucleoside reverse transcriptase inhibitors (NRTIs) Journal of the Medical Association of Thailand 89(10): 1713-1720
Ripamonti, D.; Maggiolo, F. 2008: Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection Current Opinion in Investigational Drugs 9(8): 899-912
Dieterich, D.T. 2003: Long-term complications of nucleoside reverse transcriptase inhibitor therapy Aids Reader 13(4): 176-184; 187
Peng, Z-Gen.; Chen, H-Shan.; Wang, L.; Liu, G. 2008: Anti-HIV activities of HIV-1 reverse transcriptase inhibitor racemic 11-demethyl-calanolide A Yao Xue Xue Bao 43(5): 456-460
Gupta, K.M.; Pearce, S.M.; Poursaid, A.E.; Aliyar, H.A.; Tresco, P.A.; Mitchnik, M.A.; Kiser, P.F. 2008: Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1 Journal of Pharmaceutical Sciences 97(10): 4228-4239
McMahon, J.B.; Buckheit, R.W.; Gulakowski, R.J.; Currens, M.J.; Vistica, D.T.; Shoemaker, R.H.; Stinson, S.F.; Russell, J.D.; Bader, J.P.; Narayanan, V.L.; Schultz, R.J.; Brouwer, W.G.; Felauer, E.E.; Boyd, M.R. 1996: Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor Journal of Pharmacology and Experimental Therapeutics 276(1): 298-305
Puthanakit, T.; Jourdain, G.; Hongsiriwon, S.; Suntarattiwong, P.; Chokephaibulkit, K.; Sirisanthana, V.; Kosalaraksa, P.; Petdachai, W.; Hansudewechakul, R.; Siangphoe, U.; Suwanlerk, T.; Ananworanich, J.; Bunupuradah, T.; Phasomsap, C.; Kaew-on, P.; Kanjanavanit, S.; Hinjiranandana, T.; Layangool, P.; Kamonpakorn, N.; Buranabanjasatean, S.; Ngampiyaskul, C.; Chotpitayasunondh, T.; Chanpradub, S.; Leawsrisuk, P.; Chearskul, S.; Vanprapar, N.; Phongsamart, W.; Lapphra, K.; Chearskul, P.; Wittawatmongkol, O.; Prasitsuebsai, W.; Intalapaporn, K.; Kongstan, N.; Pannin, N.; Maleesatharn, A.; Khumcha, B.; Aurpibul, L.; Wongnum, N.; Nadsasarn, R.; Lumbiganon, P.; Tharnprisan, P.; Udompanich, T.; Yentang, M.; Khonponoi, A.; Maneerat, N.; Denjunta, 2010: HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy HIV Medicine 11(9): 565-572
César, G.ía.-Z.úa.J.; Alfonso, M.-G.G.; Marius, M.ú-M.; Elizabeth, E.-M.ño.; Angel, C.-B.M.; Maira, H.-R.; Guadalupe, C.-L.M.ía.; Manuel, J.én.-E.; Ricardo, R.-C. 2011: Inhibition of HIV-1 reverse transcriptase, toxicological and chemical profile of Calophyllum brasiliense extracts from Chiapas, Mexico Fitoterapia 82(7): 1027-1034
Aurpibul, L.; Puthanakit, T.; Taecharoenkul, S.; Sirisanthana, T.; Sirisanthana, V. 2009: Reversal of growth failure in HIV-infected Thai children treated with non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy Aids Patient Care and Stds 23(12): 1067-1071
Weidle, P.J.; Moore, D.; Mermin, J.; Buchacz, K.; Were, W.; Downing, R.; Kigozi, A.; Ndazima, V.; Peters, P.; Brooks, J.T. 2008: Liver enzymes improve over twenty-four months of first-line non-nucleoside reverse transcriptase inhibitor-based therapy in rural Uganda Aids Patient Care and Stds 22(10): 787-795
Germanaud, D.; Derache, A.; Traore, M.; Madec, Y.; Toure, S.; Dicko, F.; Coulibaly, H.; Traore, M.; Sylla, M.; Calvez, V.; Marcelin, A.-G. 2010: Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali Journal of Antimicrobial ChemoTherapy 65(1): 118-124
Lee, B.; Aurpibul, L.; Sirisanthana, V.; Mangklabruks, A.; Sirisanthana, T.; Puthanakit, T. 2009: Low prevalence of insulin resistance among HIV-infected children receiving nonnucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thailand HIV Medicine 10(2): 72-78
Kantor, R.; Katzenstein, D. 2003: Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution Aids Reviews 5(1): 25-35
Voorman, R.L.; Maio, S.M.; Hauer, M.J.; Sanders, P.E.; Payne, N.A.; Ackland, M.J. 1998: Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: probable involvement of CYP2D6 and CYP3A Drug Metabolism and Disposition: the Biological Fate of Chemicals 26(7): 631-639
Mankhatitham, W.; Lueangniyomkul, A.; Manosuthi, W. 2011: Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen Southeast Asian Journal of Tropical Medicine and Public Health 42(3): 651-658
Duvivier, C.; Ghosn, J.; Assoumou, L.; Soulié, C.; Peytavin, G.; Calvez, V.; Génin, M.èl.A.é; Molina, J.-M.; Bouchaud, O.; Katlama, C.; Costagliola, D.; Beucler, I.; Dion, E.; Raffi, F.; Delfraissy, J.F.; Commoy, M.J.; Massip, P.; Garraffo, R.; Mazetier, L.; Izopet, J.; Chêne, G.; Racheline, A.; Jarousse, B.; Abgrall, S.; Obenga, G.; Phung, B.; Gerbe, J.; Bentata, M.; Honoré, P.; Rami, A.; Delcey, V.; Drener, M.; Parrinello, M.; Miailhes, P.; Lebouche, B.; Kouadjo, K.; Benmakhlouf, N.; Goujard, C.; Miquel, A.; Quetainmont, Y.; Rannou, M.T.; Perronne, C.; de Truchis, P.; Berthé, H.; Jeantils, V.; Tassi, S.; Rozenbaum, W.; Slama, L.; Chakvetaze, C.; Galanaud, P.; Boué, F.; Delavalle, A.M.; Lefebvre, B.; Bollens, D.; Meynard, J.L.; Oua 2008: Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial Journal of Antimicrobial ChemoTherapy 62(4): 797-808
Lanchy, J.M.; Ehresmann, C.; Le Grice, S.F.; Ehresmann, B.; Marquet, R. 1996: Binding and kinetic properties of HIV-1 reverse transcriptase markedly differ during initiation and elongation of reverse transcription EMBO Journal 15(24): 7178-7187
Ricchetti, M.; Buc, H. 1997: Telomerase activity of reverse transcriptase Science 277(5328): 887